NeuroThera Labs Inc. has entered into a definitive share purchase agreement to acquire approximately 54.01% of CliniQuantum Ltd., a quantum technology company developing a next-generation platform to transform clinical trials with quantum computing. This transaction positions NeuroThera to integrate quantum simulation technology into pharmaceutical research, aiming to unlock insights from massive, complex datasets that could lead to smarter, faster, and more adaptive clinical studies.
Under the agreement, NeuroThera will acquire 56,375 CliniQuantum shares in exchange for issuing 56,600,000 common shares valued at approximately $9,459,954.20 based on the 20-day volume weighted average trading price on the TSX Venture Exchange. The transaction includes potential earn-out payments of up to US$2,500,000 contingent upon CliniQuantum achieving specific milestones, including US$500,000 for each of the first three patent applications filed with the United States Patent and Trademark Office or European Patent Office, and 7.0% of any fundraising proceeds raised by NeuroThera up to US$1,000,000. These earn-out payments are payable during the three-year period following the transaction's closing.
The strategic importance of this acquisition lies in the potential to revolutionize clinical trial methodology through quantum computing. Traditional clinical trials often struggle with the complexity and volume of data generated during pharmaceutical research. CliniQuantum's quantum-based Monte Carlo technology could enable researchers to simulate complex biological systems and trial scenarios with unprecedented accuracy and speed. This technological integration could significantly reduce trial durations, improve patient selection criteria, and enhance the overall efficiency of drug development processes.
Transaction closing is expected within 30 days following submission of the Israeli tax ruling application, subject to TSXV approval and satisfaction of all closing conditions. The company will pay finder's fees by issuing 2,829,999 common shares to certain arm's length finders. All shares issued in connection with the transaction will be subject to a statutory hold period of four months plus one day from the date of issuance, as well as any additional hold periods or escrow requirements imposed by the TSXV.
This acquisition represents a significant convergence of biotechnology and quantum computing, two fields that have traditionally operated independently. The integration of quantum simulation into clinical trials could address longstanding challenges in pharmaceutical research, including the high failure rates of clinical trials and the enormous costs associated with traditional trial methodologies. As noted in the company's public filings available on https://www.sedarplus.ca, the transaction involves known and unknown risks and uncertainties, including the successful completion of the transaction, obtaining required regulatory approvals, and general business and economic uncertainties. The forward-looking statements in the announcement emphasize that actual results may differ materially from projections, though the strategic implications of combining quantum computing with clinical trial design could potentially transform how pharmaceutical companies approach drug development and testing.
